Book Text

667

REFERENCES

1. Burnstock G: The first von Euler lecture in physiology: The changing face of autonomic neurotransmission. Acta Physiol Scand 126:67, 1986.

2. Burnstock G: Autonomic neuromuscular junctions: Current developments and future directions. J Anat 146:1, 1986.

3. Burnstock G: Sympathetic purinergic transmission in small blood vessels. Trends Pharmacol Sci 9:116, 1988.

4. Burnstock G: Do some nerve cells release more than one transmitter? Neuroscience 1:239, 1976.

5. Bartfai T, Iverfeldt K, Fisone G, et al: Regulation of the release of coexisting neurotransmitters. Annu Rev Pharmacol Toxicol 28:285, 1988.

6. Von Kügelgen I, Starke K: Noradrenaline-ATP co-transmission in the sympathetic nervous system. Trends Pharmacol Sci 12:319, 1991.

7. Burnstock G: Local mechanisms of blood flow control by perivascular nerves and endothelium. J Hypertens Suppl 8:S95, 1990.

8. Ralevic V, Burnstock G: Receptors for purines and pyrimidines. Pharmacol Rev 50:413, 1998.

9. Jacobson KA, Trivedi BK, Churchill PC, et al: Novel therapeutics acting via purine receptors. Biochem Pharmacol 41:1399, 1991.

10. Burnstock G: Overview: Purinergic mechanisms. Ann N Y Acad Sci 603:1, 1990.

11. Goncalves J, Guimaraes S: Influence of neuronal uptake on pre- and postjunctional effects of α-adrenoceptor agonists in tissues with noradrenaline: ATP cotransmission. Naunyn Schmiedebergs Arch Pharmacol 344:532, 1991.

12. Hirst G, Bramich N, Edwards F, et al: Transmission at autonomic neuroeffector junctions. Trends Neurosci 15:40, 1992.

13. Walker P, Grouzmann E, Burnie M, et al: The role of neuropeptide Y in cardiovascular regulation. Trends Pharmacol Sci 12:111, 1991.

14. Lincoln J, Burnstock G: Neural-endothelial interactions in control of local blood flow. In Warren J (ed): The Endothelium: An Introduction to Current Research. New York, Wiley-Liss, 1990, p 21.

15. Lundberg JM, Rudehill A, Sollevi A, et al: Frequency- and reserpine-dependent chemical coding of sympathetic transmission: Differential release of noradrenaline and neuropeptide Y from pig spleen. Neurosci Lett 63:96, 1986.

16. Bloom S, Edwards A: Vasoactive intestinal polypeptide in relation to atropine resistant vasodilatation in the submaxillary gland of the cat. J Physiol 300:41, 1980.

17. Lundberg JM: Evidence for coexistence of vasoactive intestinal polypeptide (VIP) and acetylcholine in neurons of cat exocrine glands: Morphological, biochemical and functional studies. Acta Physiol Scand Suppl 496:1, 1981.

18. Mione M, Cavanagh J, Lincoln J, et al: Pregnancy reduces noradrenaline but not neuropeptide levels in the uterine artery of the guinea pig. Cell Tissue Res 259:503, 1990.

19. Furness JB, Costa M: The Enteric Nervous System. New York, Churchill Livingstone, 1987.

20. Bridenbaugh PO, Greene NM: Spinal (subarachnoid) neural blockade. In Cousins M, Bridenbaugh P (eds): Neural Blockade in Clinical Anesthesia and Pain Management, 2nd ed. Philadelphia, JB Lippincott, 1988, p 213.

21. Rajfer J, Aronson WJ, Bush PA, et al: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 326:90, 1992.

22. Ruffolo R: Physiology and biochemistry of the peripheral autonomic nervous system. In Wingard L, Brody T, Larner J, et al (eds): Human Pharmacology: Molecular to Clinical. St. Louis, Mosby-Year Book, 1991, p 77.

23. Fleisher LA, Frank SM, Shir Y, et al: Cardiac sympathovagal balance and peripheral sympathetic vasoconstriction: Epidural versus general anesthesia. Anesth Analg 79:165, 1994.

24. Lefkowitz R, Hoffman B, Taylor P: Drugs acting at synaptic and neuroeffector junctional sites. In Gilman A, Rall T, Nies A, et al (eds): Goodman and Gilman's the Pharmacological Basis of Therapeutics, 8th ed. New York, Pergamon Press, 1990, p 84.

25. Hoffman B, Lefkowitz R: Adrenergic receptors in the heart. Annu Rev Physiol 44:475, 1982.

26. Goldstein DS, Ziegler MG, Lake CR: Plasma norepinephrine in essential hypertension. In Ziegler M, Lake C (eds): Frontiers of Clinical Neuroscience, vol 2. Baltimore, Williams & Wilkins, 1984, p 389.

27. Ottolenghi D: Su i nervi del midollo delle ossa. Atti R Accad Sci Torino 36:939, 1903.

28. Radu A, Dahl G, Loewenstein WR: Hormonal regulation of cell junction permeability: Upregulation by catecholamine and prostaglandin E₁ . J Membr Biol 70:239, 1982.

29. Dimsdale J, Moss J: Plasma catecholamines in stress and exercise. JAMA 243:340, 1980.

30. Philipson LH: β-Agonists and metabolism. J Allergy Clin Immunol 110(Suppl 6):S313, 2001.

31. Kharasch ED, Bowdle T: Hypokalemia before induction of anesthesia and prevention by beta 2 adrenoceptor antagonism. Anesth Analg 72:216, 1991.

32. Williams ME, Gervino EV, Rosa RM, et al: Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med 312:823, 1985.

33. Struthers AD, Reid JL: The role of adrenal medullary cate-cholamines in potassium homoeostasis. Clin Sci 66:377, 1984.

34. Brown M: Hypokalemia from β2-receptor stimulation by circulating epinephrine. Am J Cardiol 56:3D, 1985.

35. Vincent HH, Man in't Veld AJ, Boomsma F, Schalekamp MA: Prevention of epinephrine-induced hypokalemia by nonselective beta blockers. Am J Cardiol 56:10D, 1985.

36. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373, 1980.

37. Johns RA: EDRF/nitric oxide: The endogenous nitrovasodilator and a new cellular messenger. Anesthesiology 75:927, 1991.

38. Snyder SH, Bredt DS: Biological roles of nitric oxide. Sci Am 266:68, 1992.

39. Bredt DS, Hwang PM, Snyder SH: Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 347:768, 1990.

40. Bredt DS, Snyder S: Nitric oxide, a novel neuronal messenger. Neuron 8:3, 1992.

41. Forstermann U, Schmidt H, Pollock J, et al: Isoforms of nitric oxide synthase: Characterization and purification from different cell types. Biochem Pharmacol 42:1849, 1991.

42. Petros A, Bennett D, Vallance P: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338:1557, 1991.

43. Bredt DS, Hwang PM, Glatt CE, et al: Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 351:714, 1991.

44. Rees DD, Palmer R, Moncada S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A 86:3375, 1989.

45. Koesling D, Böhme D, Schultz G: Guanylyl cyclases, a growing family of signal-transducing enzymes. FASEB J 5:2785, 1991.

46. Sakurai T, Yanagisawa M, Masaki T: Molecular characterization of endothelin receptors. Trends Pharmacol Sci 13:103, 1992.

47. Nava E, Palmer R, Moncada S: Inhibition of nitric oxide synthesis in septic shock: How much is beneficial? Lancet 338:1555, 1991.

48. Moore K, Wendon J, Frazer M, et al: Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327:1774, 1992.

49. Shepherd J, Vanhoutte P: Neurohumoral regulation. In Shepherd S, Vanhoutte P (eds): The Human Cardiovascular System: Facts and Concepts. New York, Raven Press, 1979, p 107.

50. Conlay L, Maher TJ, Wurtman RJ: Tyrosine increases blood pressure in hypotensive rats. Science 212:559, 1981.

51. Nussdorfer GG: Paracrine control of adrenal cortical function by medullary chromaffin cells. Pharmacol Rev 48:495, 1996.

668

52. Kamiya H, Zucker RS: Residual Ca²⁺ and short-term synaptic plasticity. Nature 371:603, 1994.

53. Zucker RS: Exocytosis: A molecular and physiological perspective. Neuron 17:1049, 1996.

54. Katz B: Nerve, Muscle, and Synapse. New York, McGraw-Hill, 1966.

55. Südhof TC, Jahn R: Proteins of synaptic vesicles involved in exocytosis and membrane recycling. Neuron 6:665, 1991.

56. DeBello WM, O'Connor V, Dresbach T, et al: SNAP-mediated protein-protein interactions essential for neurotransmitter release. Nature 373:626, 1995.

57. Bommert K, Charlton MP, DeBello WM, et al: Inhibition of neurotransmitter release by C2-domain peptides implicates synaptotagmin in exocytosis. Nature 363:163, 1993.

58. Geppert M, Goda Y, Hammer RE, et al: Synaptotagmin I: A major Ca²⁺ sensor for transmitter release at a central synapse. Cell 79:717, 1994.

59. Jahn R, Sudhof TC: Membrane fusion and exocytosis. Annu Rev Biochem 68:863, 1999.

60. Sudhof TC: The synaptic vesicle cycle revisited. Neuron 28:317, 2000.

61. Schiavo G, Rossetto O, Montecucco C: Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release. Semin Cell Biol 5:221, 1994.

62. Morgan A, Burgoyne RD: A role for soluble NSF attachment proteins (SNAPs) in regulated exocytosis in adrenal chromaffin cells. EMBO J 14:232, 1995.

63. Bennett MK, Scheller RH: A molecular description of synaptic vesicle membrane trafficking. Annu Rev Biochem 63:63, 1994.

64. Rothman JE: Mechanisms of intracellular protein transport. Nature 372:55, 1994.

65. Katz B, Miledi R: The effect of temperature on the synaptic delay at the neuromuscular junction. J Physiol 181:656, 1965.

66. Betz WJ, Bewick GS: Optical monitoring of transmitter release and synaptic vesicle recycling at the frog neuromuscular junction. J Physiol 460:287, 1993.

67. Ryan TA, Smith SJ: Vesicle pool mobilization during action potential firing at hippocampal synapses. Neuron 14:983, 1995.

68. Ryan TA, Reuter H, Wendland B, et al: The kinetics of synaptic vesicle recycling measured at single presynaptic boutons. Neuron 11:713, 1993.

69. Von Gersdorff H, Matthews G: Dynamics of synaptic vesicle fusion and membrane retrieval in synaptic terminals. Nature 367:735, 1994.

70. Eisenhofer G: In vivo kinetics of catecholamines. J Auton Pharmacol 14:7, 1994.

71. Stevens CF, Williams JH: "Kiss and run" exocytosis at hippocampal synapses. Proc Natl Acad Sci U S A 97:12828, 2000.

72. Murthy VN, Stevens CF: Reversal of synaptic vesicle docking at central synapses. Nat Neurosci 2:503, 1999.

73. Pyle JL, Kavalali ET, Piedras-Renteria ES, Tsien RW: Rapid reuse of readily releasable pool vesicles at hippocampal synapses. Neuron 28:221, 2000.

74. Moro MA, Lopez MG, Gandia L, et al: Separation and culture of living adrenaline and noradrenaline-containing cells from bovine adrenal medulla. Anal Biochem 185:243, 1990.

75. Livett BG, Marley PD: Effects of opioid peptides and morphine on histamine-induced catecholamine secretion from cultured, bovine adrenal chromaffin cells. Br J Pharmacol 89:327, 1986.

76. Marley PD, Livett BG: Differences between the mechanism of adrenaline and noradrenaline secretion from isolated, bovine, adrenal chromaffin cells. Neurosci Lett 77:81, 1987.

77. Owen PJ, Plevin R, Boarder MR: Characterization of bradykinin-stimulated release of noradrenaline from cultured bovine adrenal chromaffin cells. J Pharmacol Exp Ther 248:1231, 1989.

78. Cahill A, Perlman RL: Phorbol esters cause preferential secretion of norepinephrine from bovine chromaffin cells. J Neurochem 58:768, 1992.

79. Pacholczyk T, Blakely RD, Amara SG: Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350:350, 1991.

80. Eisenhofer G: The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91:35, 2001.

81. Sole MJ, Drobac M, Schwartz L, et al: The extraction of circulating catecholamines by the lungs in normal man and in patients with pulmonary hypertension. Circulation 60:160, 1979.

82. Moss J, Lappas D, Slater E: Role of the renin catecholamine system in hemodynamic performance in man. In Usdin E, Kvetnansky R, Kopin IJ (eds): Catecholamines and Stress: Recent Advances in Neurosciences. New York, Elsevier, 1980, p 513.

83. Kaye DM, Lambert GW, Lefkovits J, et al: Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 23:570, 1994.

84. Cohn J, Levine T, Olivari M, et al: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819, 1984.

85. Bristow M: The adrenergic nervous system in heart failure [editorial]. N Engl J Med 311:850, 1984.

86. Eisenhofer G, Friberg P, Rundqvist B, et al: Cardiac sympathetic nerve function in congestive heart failure. Circulation 93:1667, 1996.

87. Port JD, Gilbert EM, Larrabee P, et al: Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation 81:929, 1990.

88. Lake CR, Chernow B, Feuerstein G, et al: The sympathetic nervous system in man, its evaluation and the measurement of plasma norepinephrine. In Ziegler M, Lake C (eds): Frontiers of Clinical Neuroscience, vol 2. Baltimore, Williams & Wilkins, 1984, p 1.

89. Kopin IJ: False neurochemical transmitters and the mechanism of sympathetic blockade by monoamine oxidase inhibitors. J Pharmacol Exp Ther 147:186, 1965.

90. Trendelenburg U: Functional aspects of the neuronal uptake of noradrenaline. Trends Pharmacol Sci 12:334, 1991.

91. Lawhead R, Blaxall H, Bylund D: α2A is the predominant α2-adrenergic receptor subtype in human spinal cord. Anesthesiology 77:983, 1992.

92. Bylund DB: Subtypes of α1- and α2-adrenergic receptors. FASEB J 6:832, 1992.

93. Szabo B, Hedler L, Starke K: Peripheral presynaptic and central effects of clonidine, yohimbine and rauwolscine on the sympathetic nervous system in rabbits. Naunyn Schmiedebergs Arch Pharmacol 340:648, 1989.

94. Ongioco RR, Richardson CD, Rudner XL, et al: Alpha2-adrenergic receptors in human dorsal root ganglia: Predominance of alpha2b and alpha2c subtype mRNAs. Anesthesiology 92:968, 2000.

95. Michelotti GA, Price DT, Schwinn DA: Alpha 1-Adrenergic receptor regulation: Basic science and clinical implications. Pharmacol Ther 88:281, 2000.

96. Walston J, Silver K, Bogardus C, et al: Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β3-adrenergic-receptor gene. N Engl J Med 333:343, 1995.

97. Widen E, Lehto M, Kanninen T, et al: Association of a polymorphism in the β3-adrenergic receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 333:348, 1995.

98. Clement K, Vaisse C, Manning BSF, et al: Genetic variation in the β3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 333:352, 1995.

99. Hall IP, Wheatley A, Wilding P, et al: Association of Glu27 β2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 345:1213, 1995.

100. Turki J, Pak J, Green SA, et al: Genetic polymorphisms of the β2-adrenergic receptor in nocturnal and non-nocturnal asthma: Evidence that Gly 16 correlates with the nocturnal phenotype. J Clin Invest 95:1635, 1995.

669

101. Mason DA, Moore JD, Green SA, et al: A gain-of-function polymorphism in a G-protein coupling domain of the human beta 1-adrenergic receptor. J Biol Chem 274:12670, 1999.

102. Small KM, Wagoner LE, Levin AM, et al: Synergistic polymorphisms of β1- and α2c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135, 2002.

103. Hausdorff WP, Caron MG, Lefkowitz RJ: Turning off the signal: Desensitization of β-adrenergic receptor function. FASEB J 4:2881, 1990.

104. Michel MC, Kenny B, Schwinn DA: Classification of α1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 352:1, 1995.

105. Boehm S, Kubista H: Fine tuning of sympathetic transmitter release via ionotropic and metabotropic presynaptic receptors. Pharmacol Rev 54:43, 2002.

106. Szabo B, Schramm A, Starke K: Effect of yohimbine on renal sympathetic nerve activity and renal norepinephrine spillover in anesthetized rabbits. J Pharmacol Exp Ther 260:780, 1992.

107. Limberger N, Singer EA, Starke K: Only activated but not non-activated presynaptic α2-autoreceptors interfere with neighboring presynaptic receptor mechanisms. Naunyn Schmiedebergs Arch Pharmacol 338:62, 1988.

108. Opie L: Receptors and signal transduction. In Opie LH (ed): The Heart: Physiology and Metabolism. New York, Raven Press, 1991.

109. Raymond J, Hnatowich M, Lefkowitz R, et al: Adrenergic receptors: Models for regulation of signal transduction processes. Hypertension 15:119, 1990.

110. Vanhees L, Aubert A, Fagard R, et al: Influence of β1- versus β2-adrenoceptor blockade on left ventricular function in humans. J Cardiovasc Pharmacol 8:1086, 1986.

111. Opie L: Ventricular overload and heart failure. In Opie LH (ed): The Heart: Physiology and Metabolism, 2nd ed. New York, Raven Press, 1991, p 386.

112. Brodde O: The functional importance of β1- and β2-adrenoceptors in the human heart. Am J Cardiol 62:24C, 1988.

113. Goldberg LI, Rajfer SI: Dopamine receptors: Applications in clinical cardiology. Circulation 72:245, 1985.

114. Bertorello A, Aperia A: Both DA1 and DA2 receptor agonists are necessary to inhibit Na+/K+ ATPase activity in proximal tubules from the rat kidney. Acta Physiol Scand 132:441, 1988.

115. Bertorello A, Aperia A: Regulation of Na+/K+ ATPase activity in kidney proximal tubules: Involvement of GTP binding proteins. Am J Physiol 256:F57, 1989.

116. Gesek FA, Schoolwerth AC: Hormonal interactions with the proximal Na+/H+ exchanger. Am J Physiol 258:F514, 1990.

117. Linder ME, Gilman AG: G Proteins. Sci Am 267:56, 1992.

118. Pang IH, Sternweis PC: Purification of unique α subunits of GTP-binding regulatory proteins (G proteins) by affinity chromatography with immobilized βγ subunits. J Biol Chem 265:18707, 1990.

119. Blank JL, Ross AH, Exton JH: Purification and characterization of two G-proteins that activate the β1 isozyme of phosphoinositide-specific phospholipase C. J Biol Chem 266:18206, 1991.

120. Gutowski S, Smrcka A, Nowak L, et al: Antibodies to the αq subfamily of guanine nucleotide-binding regulatory protein α subunits attenuate activation of phosphatidylinositol 4,5-bisphosphate hydrolysis by hormones. J Biol Chem 266:20519, 1991.

121. Alousi AA, Jasper JR, Insel PA, et al: Stoichiometry of receptor Gs-adenylate cyclase interactions. FASEB J 5:2300, 1991.

122. Post SR, Hilal-Dandan R, Urasawa K, et al: Quantification of signaling components and amplification in the β-adrenergic receptor-adenylate cyclase pathway in isolated adult rat ventricular myocytes. Biochem J 311:75, 1995.

123. Yatani A, Okabe K, Codina J, et al: Heart rate regulation by G proteins acting on the cardiac pacemaker channel. Science 249:1163, 1990.

124. Roizen M, Horrigan R, Frazier B: Anesthetic doses blocking adrenergic stress and cardiovascular responses to incision: MAC BAR. Anesthesiology 54:390, 1981.

125. Roizen MF, Thoa NB, Moss J, et al: Inhibition by halothane of release of norepinephrine, but not of dopamine-β-hydroxylase, from guinea pig vas deferens. Eur J Pharmacol 31:313, 1975.

126. Rorie DK, Tyce GM, Mackenzie RA: Evidence that halothane inhibits norepinephrine release from sympathetic nerve endings in dog saphenous vein by stimulation of presynaptic inhibitory muscarinic receptors. Anesth Analg 63:1059, 1984.

127. Lunn JJ, Rorie DK: Halothane-induced changes in the release and disposition of norepinephrine at adrenergic nerve endings in dog saphenous vein. Anesthesiology 61:377, 1984.

128. Bernstein KJ, Gangat Y, Verosky M, et al: Halothane effect on β-adrenergic receptors in canine myocardium. Anesth Analg 60:401, 1981.

129. Bernstein K, Verosky M, Triner L: Halothane inhibition of canine myocardial adenylate cyclase: Modulation by endogenous factors. Anesth Analg 63:285, 1984.

130. Gangat Y, Vuliemoz Y, Verosky M, et al: Action of halothane on myocardial adenylate cyclase of rat and cat. Proc Soc Exp Biol Med 160:154, 1979.

131. Narayanan TK, Confer RA, Dennison RL, et al: Halothane attenuation of muscarinic inhibition of adenylate cyclase in rat heart. Biochem Pharmacol 37:1219, 1988.

132. Vulliemoz V, Verosky M, Triner L: Effect of halothane on myocardial cyclic AMP and cyclic GMP content of mice. J Pharmacol Exp Ther 236:181, 1986.

133. Thurston T, Glusman S: Halothane myocardial depression: Interactions with the adenylate cyclase system. Anesth Analg 75:63, 1993.

134. Terrar DA, Victory JG: Effects of halothane on membrane currents associated with contraction in single myocytes from guinea pig ventricle. Br J Pharmacol 94:500, 1988.

135. Lynch C, Vogel S, Sperelakis N: Halothane depression of myocardial slow action potentials. Anesthesiology 55:360, 1988.

136. Komai H, Rusy BF: Direct effect of halothane and isoflurane on the function of the sarcoplasmic reticulum in intact rabbit atria. Anesthesiology 72:694, 1990.

137. Su JY, Kerrick WG: Effects of halothane on caffeine-induced tension transients in functionally skinned myocardial fibers. Pflugers Arch 380:29, 1979.

138. Blochl-Daum B, Schuller-Petrovic S, Wolzt M, et al: Primary defect in α-adrenergic responsiveness in patients with varicose veins. Clin Pharmacol Ther 49:49, 1991.

139. Insel PA: Adrenergic receptors: Evolving concepts and clinical implications. N Engl J Med 334:580, 1996.

140. Bristow MR, Ginsburg R, Minobe W, et al: Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med 307:205, 1982.

141. Menard L, Ferguson SS, Zhang J, et al: Synergistic regulation of β2-adrenergic receptor sequestration: Intracellular complement of β-adrenergic receptor kinase and β-arrestin determine kinetics of internalization. Mol Pharmacol 51:800, 1997.

142. Ferguson SS, Barak LS, Zhang J, et al: G-protein-coupled receptor regulation: Role of G-protein-coupled receptor kinases and arrestins. Can J Physiol Pharmacol 74:1095, 1996.

143. Hedberg A, Kemp F Jr, Josephson ME, et al: Co-existence of β1- and β2-adrenergic receptors in the human heart: Effects of treatment with receptor antagonists or calcium entry blockers. J Pharmacol Exp Ther 234:561, 1985.

144. Bristow M, Ginsburg R, Umans V, et al: β1- and β2-adrenergic receptor subpopulations in non-failing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective β1 receptor downregulation in heart failure. Circ Res 59:297, 1986.

145. Hedberg A: Adrenergic receptors: Methods of determination and mechanisms of regulation. Acta Med Scand Suppl 672:7, 1983.

146. Dratman M, Crutchfield F, Axelrod J, et al: Localization of triiodothyronine in nerve ending fractions of rat brain. Proc Natl Acad Sci U S A 73:941, 1976.

670

147. Doukas PH: Drugs affecting the parasympathetic nervous system. In Wingard L, Brody T, Larner J, et al (eds): Human Pharmacology: Molecular to Clinical. St. Louis, Mosby-Year Book, 1991.

148. Conlay L, Wurtman RJ, Blusztaj K, et al: Decreased plasma choline concentrations in marathon runners. N Engl J Med 86:892, 1986.

149. Stiller R: Neuromuscular blocking agents. In Wingard L, Brody T, Larner J, et al (eds): Human Pharmacology: Molecular to Clinical. St. Louis, Mosby-Year Book, 1991.

150. Soreq H, Zakut H: Amplification of butyrylcholinesterase and acetylcholinesterase genes in normal and tumor tissues: Putative relationship to organophosphorus poisoning. Pharm Res 7:1, 1990.